Skip to main content
Top
Published in: Cancer Causes & Control 5/2006

01-06-2006 | Review Article

The Future of Cancer Surveillance

Author: Robert A. Hiatt

Published in: Cancer Causes & Control | Issue 5/2006

Login to get access

Abstract

Cancer surveillance is entering an exciting era where the scope of its activities will be expanded and the amount, quality, and depth of information on cancer will be richer and more readily available to practitioners, decision makers and the public. This future is being built on a solid history of accomplishment that has placed cancer foremost among all chronic diseases in the organization and implementation of a systematic and integrated monitoring enterprise that is of essential value in both clinical medicine and public health. The future of cancer surveillance will be driven not only by innovations in methods of cancer surveillance itself, but also by developments in information technology and communication and by revolutionary new tools used in the delivery of medical care. At the same time, it will be a challenge to ensure levels of privacy and confidentiality needed to maintain the public trust. In the Cancer Surveillance and Information Summit, a 2004 conference sponsored by C-Change, experts from the field and from allied and related disciplines in both the public and private sectors met to consider the future of the cancer surveillance enterprise. Seven recommendations, detailed in this article, emerged from the conference to guide future growth and development. Steps that can and should be taken by all individuals and groups involved in cancer surveillance were included. The shared view is that cancer surveillance and information is essential to fulfill a vision for a future where cancer is prevented, detected early, and either cured or managed successfully as a chronic illness.
Footnotes
1
C-Change is a non-profit and multi-sector national cancer collaborative that collectively strives to address issues related to the full continuum of cancer care and control. [http://www.c-changetogether.org/].
 
Literature
1.
go back to reference Cancer surveillance futures project. April 2001. http://www.ndoc.org/about_ndc/reports/surveillance.asp Cancer surveillance futures project. April 2001. http://​www.​ndoc.​org/​about_​ndc/​reports/​surveillance.​asp
2.
go back to reference Cancer surveillance research implementation plan. Surveillance Implementation Group, National Cancer Institute, National Institutes of Health, March 1999. http://cancercontrol.cancer.gov/sig/ Accessed January 22, 2005 Cancer surveillance research implementation plan. Surveillance Implementation Group, National Cancer Institute, National Institutes of Health, March 1999. http://​cancercontrol.​cancer.​gov/​sig/​ Accessed January 22, 2005
3.
go back to reference C-Change: collaborating to conquer cancer. (formerly the National Dialogue on Cancer) (http://www.ndoc.org/default.asp). Accessed January 22 2005 C-Change: collaborating to conquer cancer. (formerly the National Dialogue on Cancer) (http://​www.​ndoc.​org/​default.​asp). Accessed January 22 2005
4.
go back to reference Comprehensive cancer control planning. Centers for Disease Control and Prevention (http://www.cdc.gov/cancer/ncccp/toolkit/index.htm) Comprehensive cancer control planning. Centers for Disease Control and Prevention (http://​www.​cdc.​gov/​cancer/​ncccp/​toolkit/​index.​htm)
5.
go back to reference Deapen D (2005) Impact of privacy and confidentiality concerns. a report from the cancer surveillance and information summit. Cancer Causes Control (under review) Deapen D (2005) Impact of privacy and confidentiality concerns. a report from the cancer surveillance and information summit. Cancer Causes Control (under review)
6.
go back to reference Detmer DE (2003) Building the national health information infrastructure for personal health, health care services, public health, and research. BMC Med Inform Decis Mak 3:1CrossRefPubMed Detmer DE (2003) Building the national health information infrastructure for personal health, health care services, public health, and research. BMC Med Inform Decis Mak 3:1CrossRefPubMed
7.
go back to reference Gostin LO, Hodge JG Jr, Valdieserri RO (2001) Informational privacy and the public’s health: the model state public health privacy act. Am J Pub Health 91:1388–1392PubMed Gostin LO, Hodge JG Jr, Valdieserri RO (2001) Informational privacy and the public’s health: the model state public health privacy act. Am J Pub Health 91:1388–1392PubMed
8.
go back to reference Guide to community preventive services. CDC. http://www.cdc.gov/programs/partners4.htm Guide to community preventive services. CDC. http://​www.​cdc.​gov/​programs/​partners4.​htm
9.
go back to reference Hiatt RA (2003) HIPAA: The end of epidemiology, or a new social contract? (Commentary). Epidemiology 14:637–639PubMed Hiatt RA (2003) HIPAA: The end of epidemiology, or a new social contract? (Commentary). Epidemiology 14:637–639PubMed
10.
go back to reference Hiatt RA, Rimer BK (1999) A new strategy for cancer control research. Cancer Epidemiol Biomarkers Prev 11:957–964 Hiatt RA, Rimer BK (1999) A new strategy for cancer control research. Cancer Epidemiol Biomarkers Prev 11:957–964
11.
go back to reference Howe HL, Edwards BK, Young JL, Shen T, West DW, Hutton M, Correa CN (2003) A vision for cancer incidence surveillance in the United States. Cancer Causes Control 14:663–672CrossRefPubMed Howe HL, Edwards BK, Young JL, Shen T, West DW, Hutton M, Correa CN (2003) A vision for cancer incidence surveillance in the United States. Cancer Causes Control 14:663–672CrossRefPubMed
12.
go back to reference Jemal A, Clegg LX, Ward E, Ries LAG, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1) Jemal A, Clegg LX, Ward E, Ries LAG, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1)
13.
go back to reference Shortliffe EH (2005) The informatics infrastructure: anticipating its role in cancer surveillance. Cancer Causes Control (under review) Shortliffe EH (2005) The informatics infrastructure: anticipating its role in cancer surveillance. Cancer Causes Control (under review)
14.
go back to reference Sittig DF (2005) Potential impact of advanced clinical information technology on cancer care in 2015. A report from the cancer surveillance and information summit. Cancer Causes Control (under review) Sittig DF (2005) Potential impact of advanced clinical information technology on cancer care in 2015. A report from the cancer surveillance and information summit. Cancer Causes Control (under review)
15.
go back to reference Swan J, Wingo P, Clive R, West D, Miller D, Hutchison C, Sondik EJ, Edwards BK (1998) Cancer surveillance in the U.S.: can we have a national system? Cancer 83(7):1282–1291CrossRefPubMed Swan J, Wingo P, Clive R, West D, Miller D, Hutchison C, Sondik EJ, Edwards BK (1998) Cancer surveillance in the U.S.: can we have a national system? Cancer 83(7):1282–1291CrossRefPubMed
16.
go back to reference The cancer control PLANET (plan, link, act network with evidence-based tools). (http://cancercontrolplanet.cancer.gov/) The cancer control PLANET (plan, link, act network with evidence-based tools). (http://​cancercontrolpla​net.​cancer.​gov/​)
17.
go back to reference Wingo PA, Howe HL, Thun MJ, Ballard-Barbash R, Ward E, Brown ML, Sylvester J, Friedell GH, Alley L, Rowland JH, Edwards BK (2005) A national framework for cancer surveillance in the United States. Cancer Causes Control 16:151–170CrossRefPubMed Wingo PA, Howe HL, Thun MJ, Ballard-Barbash R, Ward E, Brown ML, Sylvester J, Friedell GH, Alley L, Rowland JH, Edwards BK (2005) A national framework for cancer surveillance in the United States. Cancer Causes Control 16:151–170CrossRefPubMed
18.
go back to reference Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC. Hall HI (2003) Building the infrastructure for nationwide cancer surveillance and control – a comparison between The National Program of Cancer Registries (NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14:175–193CrossRefPubMed Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC. Hall HI (2003) Building the infrastructure for nationwide cancer surveillance and control – a comparison between The National Program of Cancer Registries (NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14:175–193CrossRefPubMed
19.
go back to reference United States cancer statistics. 1999–2001 incidence and mortality: web-based report version. U.S. Cancer Statistics Working Group. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2004. Available at: www.cdc.gov/cancer/npcr/uscs. Accessed January 22, 2005. United States cancer statistics. 1999–2001 incidence and mortality: web-based report version. U.S. Cancer Statistics Working Group. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2004. Available at: www.cdc.gov/cancer/npcr/uscs. Accessed January 22, 2005.
Metadata
Title
The Future of Cancer Surveillance
Author
Robert A. Hiatt
Publication date
01-06-2006
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 5/2006
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-006-0003-0

Other articles of this Issue 5/2006

Cancer Causes & Control 5/2006 Go to the issue

Letter to the Editor

Re: Glaser et al

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine